Miracor receives $3.5 million cash infusion

The funding will be used primarily to commence the pivotal clinical trial—RAMSES—of the Company’s PICSO (Pressure-controlled Intermittent Coronary Sinus Occlusion) system.The RAMSES trial is designed to understand how PICSO can help acute coronary syndrome patients with large anterior infarcts having ECG changes with poor microcirculation after revascularization.

In a feasibility study of stable angina patients, the PICSO procedure was performed successfully in 10 patients by Prof. Dr. med. Jan Piek and his group at the Academic Medical Center, Amsterdam, The Netherlands. Based on these outstanding clinical results and the availability of fresh capital, Miracor will soon initiate the pivotal ‘RAMSES’ study in acute coronary syndrome patients.

“Despite a successful primary PCI, suboptimal myocardial reperfusion still occurs in about 30 percent of STEMI patients, and this high incidence is strongly linked to unfavorable outcomes for patients,” said Jon H. Hoem, Miracor CEO. “Our feasibility study demonstrated that PICSO clearly reduces ischemia acutely when an infarct was induced in stable angina patients, which is why we are delighted to have this new funding from FFG supporting the RAMSES pivotal clinical trial in STEMI patients,” added Hoem.

The Swiss subsidiary of Miracor "Miracor Sales and Marketing GmbH" was founded in 2008 and awarded with the CTI Start-up Label in 2010.